Lingling Zu
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Physiology top 10%
- Adenosine and Purinergic Signaling
Papers in
- Oncology 17
- Lung Cancer Research Studies 9
- Cancer Immunotherapy and Biomarkers 7
- Cancer Cells and Metastasis 2
-
- MicroRNA in disease regulation 11
- Co-authors
- Yang Li (8 shared papers)Jiacong You (5 shared papers)Song Xu (23 shared papers)Qinghua Zhou (9 shared papers)Qinghua Zhou (6 shared papers)Xuebing Li (8 shared papers)Jun Du (1 shared paper)Qing Yang (1 shared paper)
- Journals
- Cancer Medicine (4 papers)Frontiers in Oncology (3 papers)Cancers (3 papers)BMC Cancer (2 papers)Oncotarget (2 papers)
- Partner nations
- ChinaUnited StatesBrazil
In The Last Decade
Lingling Zu
52 papers receiving 820 citations
Peers
Comparison fields: 5 of 61
- Cancer Research 328
- Physiology 42
- Oncology 152
- Pulmonary and Respiratory Medicine 117
- Drug Discovery 1
Countries citing papers authored by Lingling Zu
This map shows the geographic impact of Lingling Zu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingling Zu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingling Zu more than expected).
Fields of papers citing papers by Lingling Zu
This network shows the impact of papers produced by Lingling Zu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingling Zu. The network helps show where Lingling Zu may publish in the future.
Co-authors
The 25 scholars most cited alongside Lingling Zu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 94 | |
| 2 | Erratum: MicroRNA-338-3p suppresses metastasis of lung cancer cells by targeting the EMT regulator Sox4. | 2016 | 70 |
| 3 | 2014 | 60 | |
| 4 | 2013 | 58 | |
| 5 | 2015 | 46 | |
| 6 | 2017 | 36 | |
| 7 | MiR-449a suppresses cell invasion by inhibiting MAP2K1 in non-small cell lung cancer. | 2015 | 35 |
| 8 | 2016 | 34 | |
| 9 | 2014 | 29 | |
| 10 | 2020 | 29 | |
| 11 | 2022 | 22 | |
| 12 | 2023 | 21 | |
| 13 | 2021 | 19 | |
| 14 | 2022 | 19 | |
| 15 | 2023 | 19 | |
| 16 | 2021 | 17 | |
| 17 | 2021 | 16 | |
| 18 | 2014 | 15 | |
| 19 | 2021 | 15 | |
| 20 | 2022 | 14 |
About Lingling Zu
Lingling Zu is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Geriatrics and Gerontology, having authored 54 papers that have together received 834 indexed citations. Recurring topics across this work include MicroRNA in disease regulation (11 papers), Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (9 papers), Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Diagnosis and Treatment (5 papers), Ferroptosis and cancer prognosis (4 papers), Cancer Cells and Metastasis (2 papers) and Mechanisms of cancer metastasis (2 papers). The work is most often cited by research in Cancer Research (328 citations), Physiology (42 citations), Oncology (152 citations), Pulmonary and Respiratory Medicine (117 citations) and Drug Discovery (1 citation). Lingling Zu has collaborated with scholars based in China, United States and Brazil. Frequent co-authors include Yang Li, Jiacong You, Song Xu, Qinghua Zhou, Qinghua Zhou, Xuebing Li, Jun Du, Qing Yang, Ning Zhou and Qinghua Zhou. Their work appears in journals such as Cancer Medicine, Frontiers in Oncology, Cancers, BMC Cancer and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.